Chimeric Antigen Receptors
We use Chimeric Antigen Receptors (CARs) to reprogram our T cell product candidates. These receptors combine the tumor recognition domain of an antibody with the activation and costimulatory domains from the T cell receptor to rearm a patient’s T cells to recognize and kill their cancer cells.
Advanced Cell Programing
Autolus is applying its extensive cell programing capability to develop a pipeline of precise, controlled and highly active products.
T Cell Manufacturing
We have developed our own proprietary viral vector and semi-automated cell manufacturing processes to engineer a patient's T cells with the CAR and other advanced cell programing modules.
The company’s lead therapeutic candidate, obe-cel, is a transformational treatment for adult Acute Lymphoblastic Leukemia. Obe-cel is an autologous CD19 CAR T cell therapy with a unique CD19 CAR. The CAR is designed to have a “fast-off” kinetic which mimics physiological T cell receptor interactions. Clinical trials of obe-cel have demonstrated that this enhanced kinetic profile results in increased T cell persistence leading to high levels of durable remissions and remarkably low levels of cytokine release syndrome and other immunotoxicities. Obe-cel is currently being evaluated in the potentially pivotal FELIX study in adult ALL and in phase 1 studies for other B-NHL indications.Find our more
Our Obe-cel Abstracts and Publications
Life at Autolus
Whilst working at Autolus you will enjoy a flexible, diverse and dynamic working environment which actively promotes creativity, leadership and teamwork – together we are ONE Autolus.Careers at Autolus
Autolus is committed to the development and commercialization of obe-cel in r/r Adult ALL and is progressing opportunities for obe-cel in additional indications alongside its preclinical and clinical pipeline for hematological malignancies and solid tumors.View investor information